9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Archive

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma

ConditionAdvanced Malignant Mesothelioma|Epithelial Mesothelioma|Localized Malignant Mesothelioma|Recurrent Malignant Mesothelioma|Sarcomatous MesotheliomaEstimated Enrollment: 106Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: TreatmentStudy ID Numbers: NCI-2012-02430|CDR0000069058|NCI-2710|UCCRC-11046A|11046A|2710|N01CM17102|P30CA014599Study First Received: December 7, 2001Last Updated: February 10, 2014Estimated Primary Completion Date: May 2006Primary Outcome Measures:Time to disease progression|Complete response rate|Objective response rate (complete and partial response)|Rate of disease stabilization|Overall survival|Incidence of adverse events graded according to NCI CTCAE version 3.0Sponsors and Collaborators:National Cancer Institute (NCI)Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00027703...

Continue reading

A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer

ConditionPancreatic Cancer|Mesothelioma|Ovarian Cancer|Non-Small Cell Lung CancerEstimated Enrollment: 24Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: MORAb-009-001Study First Received: May 11, 2006Last Updated: July 16, 2014Estimated Primary Completion Date: September 2008Primary Outcome Measures:Safety and Tolerability as a measure of Adverse Events/Serious Adverse Events|Safety and Tolerability as a measure of clinical laboratory parameters|Safety and Tolerability as a measure of physical examinations, vital signs, and ECGs|Pharmacokinetics of MORAb-009|Percentage of Participants With Antibodies Against Infliximab (Human Anti-chimeric Antibody [HACA])|Objective Tumor Response Rate Assessed by InvestigatorSponsors and...

Continue reading

Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma

ConditionPleural NeoplasmsEstimated Enrollment: 77Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: 7216|H3E-US-JMGAStudy First Received: July 12, 2004Last Updated: May 1, 2009Estimated Primary Completion Date: February 2008Primary Outcome Measures:Pathological Complete Response|The 1 and 2 Year Disease-Free Survival Rate (Percentage)|Overall Tumor Response|Time to Treatment Failure|Time to Progressive Disease|Overall Survival TimeSponsors and Collaborators:Eli Lilly and CompanyResult Received: February 16, 2009Website Link: https://ClinicalTrials.gov/show/NCT00087698...

Continue reading

Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura

ConditionEsophageal Cancer|Lung Cancer|Malignant Mesothelioma|Metastatic CancerEstimated Enrollment: nullAge Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Primary Purpose: TreatmentStudy ID Numbers: CDR0000067228|NCI-99-C-0129|NCI-T99-0012Study First Received: July 11, 2001Last Updated: April 28, 2015Estimated Primary Completion Date: nullPrimary Outcome Measures:Sponsors and Collaborators:National Cancer Institute (NCI)Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00019825...

Continue reading

Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma

ConditionLeukemia|Lung Cancer|Malignant Mesothelioma|Myelodysplastic Syndromes|Primary Peritoneal Cavity CancerEstimated Enrollment: 22Age Group: 18 Years to 120 Years   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: 06-085|P30CA008748|P01CA023766|MSKCC-06085Study First Received: November 9, 2006Last Updated: February 2, 2016Estimated Primary Completion Date: June 2009Primary Outcome Measures:Safety|Immune ResponseSponsors and Collaborators:Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Innovive PharmaceuticalsResult Received: December 22, 2015Website Link: https://ClinicalTrials.gov/show/NCT00398138...

Continue reading

Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.

ConditionEpithelial Mesothelioma|Recurrent Malignant Mesothelioma|Sarcomatous Mesothelioma|Stage IA Malignant Mesothelioma|Stage IB Malignant Mesothelioma|Stage II Malignant Mesothelioma|Stage III Malignant Mesothelioma|Stage IV Malignant MesotheliomaEstimated Enrollment: 44Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: NCI-2012-02813|CALGB-30307|CDR0000415372|U10CA031946Study First Received: April 5, 2005Last Updated: June 4, 2013Estimated Primary Completion Date: June 2007Primary Outcome Measures:Response rate (including complete and partial response)|Time to tumor progression|Percentage of patients remaining failure-free|Overall survivalSponsors and Collaborators:National Cancer Institute (NCI)Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00107432...

Continue reading

Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma

ConditionMalignant Pleural MesotheriomaEstimated Enrollment: 12Age Group: 20 Years to 75 Years   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: 5249|H3E-JE-ME01Study First Received: November 8, 2005Last Updated: November 5, 2007Estimated Primary Completion Date: nullPrimary Outcome Measures:To determine the recommended dose of LY231514 and cisplatin combination therapy, Response Rate|Duration of response|Progression free survival|Median survival time|1 year survival rate|Pulmonary function|QOL|Safety|Plasma concentrationSponsors and Collaborators:Eli Lilly and CompanyResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00251550...

Continue reading

Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas

ConditionLung Cancer|Esophageal Cancer|Malignant Pleural Mesothelioma|Sarcoma|Thymic CarcinomaEstimated Enrollment: 10Age Group: 18 Years to 120 Years   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Primary Purpose: TreatmentStudy ID Numbers: 100138|10-C-0138Study First Received: June 11, 2010Last Updated: April 20, 2017Estimated Primary Completion Date: February 9, 2015Primary Outcome Measures:Tabulation of toxicity type and grade|To ascertain if K526-GM vaccines induce immunity to CT antigens commonly expressed in thoracic malignancies.|To determine if metronomic oral CP and celecoxib reduce the number, percentage and function of CD4+ CD25+ Fox P3+ regulatory T cells (T reg) in peripheral blood of thoracic oncology patients.Sponsors and Collaborators:National...

Continue reading

Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma

ConditionCarcinoma, Non-Small-Cell Lung|MesotheliomaEstimated Enrollment: 18Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: CLBH589B2109Study First Received: September 26, 2007Last Updated: November 26, 2012Estimated Primary Completion Date: January 2009Primary Outcome Measures:Pharmacokinetic (PK) parameters|Response rate assessed by comparing tumor size via radiology scans (CTs or MRIs)|Safety (until disease progression, unacceptable toxicity or study completion) assessed by duration of patient participation|Tolerability (until disease progression, unacceptable toxicity or study completion) assessed by duration of patient participationSponsors and Collaborators:Novartis Pharmaceuticals|NovartisResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00535951...

Continue reading

MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC

ConditionMalignant Pleural Mesothelioma|Non-Small Cell Lung CancerEstimated Enrollment: 27Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: TreatmentStudy ID Numbers: HREC/13/CRGH/199Study First Received: January 5, 2015Last Updated: April 5, 2017Estimated Primary Completion Date: January 4, 2017Primary Outcome Measures:There is a composite primary outcome to establish maximum tolerated dose and dose limiting toxicities The MTD will be determined by the assessment of dose limiting toxicities.|to evaluate the effect of multiple dosing of TargomiRs|to detect early signs of efficacy|QOL assessment|ECOG PS change|Pulmonary function changeSponsors and Collaborators:Asbestos Diseases Research Foundation|EnGeneIC LimitedResult...

Continue reading